Evidence map›Paper›PMID 38824242›Full record

Trial reportNature medicine2024

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.

Feng Wang, Lin Shen, Weijian Guo, Tianshu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yueyin Pan and 31 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Feng Wang *Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0001-7668-9674
Lin Shen *Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China.
Weijian Guo *Fudan University Shanghai Cancer Centre, Shanghai, China.
Tianshu LiuZhongshan Hospital Fudan University, Shanghai, China.ORCID 0000-0002-8604-6311
Jin LiTongji University Shanghai East Hospital, Shanghai, China.ORCID 0000-0003-0099-874X
Shukui QinNanjing Tianyinshan Cancer Hospital of China Pharmaceutical University (CPU), Nanjing, China.
Yuxian BaiHarbin Medical University Cancer Hospital, Harbin, China.
Zhendong ChenThe Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Jufeng WangHenan Cancer Hospital, Zhengzhou, China.
Yueyin PanAnhui Provincial Hospital, Hefei, China.ORCID 0000-0003-0532-5368
Yongqian ShuThe First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China.
Fuyou ZhaoThe First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Ying ChengJilin Cancer Hospital, Changchun, China.
Feng YeThe First Affiliated Hospital of Xiamen University, Xiamen, China.
Kangsheng GuThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Tao ZhangUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hongming PanSir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Haijun ZhongZhejiang Cancer Hospital, Hangzhou, China.
Fuxiang ZhouZhongnan Hospital of Wuhan University, Wuhan, China.
Yanru QinThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lei YangNantong Tumor Hospital, Nantong, China.
Weidong MaoJiangyin People's Hospital, Jiangyin, China.
Qiu LiWest China Hospital, Sichuan University, Chengdu, China.
Wenxiang DaiThe First Affiliated Hospital of University of South China, Hengyang, China.
Wei LiThe First Bethune Hospital of Jilin University, Changchun, China.
Shubin WangPeking University Shenzhen Hospital, Shenzhen, China.
Yong TangXinjiang Medical University Cancer Hospital, Urumqi Municipality, China.
Dong MaGuangdong Provincial People's Hospital, Guangzhou, China.
Xianli YinHunan Cancer Hospital, Changsha, China.
Yanhong DengThe Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ying YuanThe Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-3922-9553
Man LiThe Second Hospital of Dalian Medical University, Dalian, China.
Wenwei HuThe First People's Hospital of Changzhou, Changzhou, China.
Donghui ChenShanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Guoxin LiNanfang Hospital of Southern Medical University, Guangzhou, China.ORCID 0000-0003-2773-7048
Qiqi LiuHUTCHMED Limited, Shanghai, China.
Panfeng TanHUTCHMED Limited, Shanghai, China.
Songhua FanHUTCHMED Limited, Shanghai, China.
Michael ShiHUTCHMED Limited, Shanghai, China.
Weiguo SuHUTCHMED Limited, Shanghai, China.
Rui-Hua XuSun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University, Guangzhou, China. xurh@sysucc.org.cn.ORCID 0000-0001-9771-8534

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vascular endothelial growth factor pathway plays a key role in the pathogenesis of gastric cancer. In the multicenter, double-blind phase 3 FRUTIGA trial, 703 patients with advanced gastric or gastroesophageal junction adenocarcinoma who progressed on fluorouracil- and platinum-containing chemotherapy were randomized (1:1) to receive fruquintinib (an inhibitor of vascular endothelial growth factor receptor-1/2/3; 4 mg orally, once daily) or placebo for 3 weeks, followed by 1 week off, plus paclitaxel (80 mg/m

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBenzofuransEsophagogastric JunctionPaclitaxelStomach NeoplasmsAdultAgedAged, 80 and overDouble-Blind MethodEsophageal NeoplasmsFemaleHumansMaleMiddle AgedProgression-Free SurvivalBenzofuransHMPL-013PaclitaxelQuinazolinesQuinolines

Identifiers

PMID38824242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.